Goodrx
GDRX

Goodrx (GDRX) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
BarclaysMaintainedUnderweight$4.00 from $3.00Aug 21, 2026
UBSMaintainedNeutral$3.75 from $2.50Aug 13, 2026
TD CowenMaintainedBuy$5.00 from $4.00Aug 11, 2026
CitigroupMaintainedBuy$5.00 from $4.00Aug 11, 2026
Wells FargoMaintainedOverweight$5.00 from $3.50Aug 7, 2026
CitigroupMaintainedBuy$4.00 from $3.50May 14, 2026
TD CowenMaintainedBuy$4.00 from $3.00May 11, 2026
Wells FargoMaintainedOverweight$3.50 from $7.00Mar 4, 2026
CitigroupMaintainedBuy$3.50 from $4.50Mar 3, 2026
Goldman SachsMaintainedNeutral$2.50 from $4.00Mar 2, 2026
JP MorganDowngradedOverweight → NeutralFeb 27, 2026
MizuhoMaintainedNeutral$3.00 from $4.00Feb 27, 2026
JefferiesDowngradedBuy → Hold$2.75 from $5.25Jan 22, 2026
CitigroupMaintainedBuy$4.50 from $5.00Jan 9, 2026
Morgan StanleyMaintainedEqual-Weight$4.00 from $5.00Dec 18, 2025
BarclaysInitiated CoverageUnderweight$3.00Dec 9, 2025
JP MorganMaintainedOverweight$5.00 from $6.00Nov 11, 2025
TD CowenMaintainedBuy$6.00 from $7.00Nov 10, 2025
MizuhoMaintainedNeutral$4.00 from $5.00Nov 6, 2025
UBSMaintainedNeutral$4.00 from $4.25Nov 6, 2025

Frequently asked questions

  • What is the latest analyst rating on GDRX?

    On Aug 21, 2026, Barclays maintained Goodrx at Underweight with a price target of $4.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.